Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 1.00 |
| ▸ | EBPL | Q9BY08 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.78 |
| ▸ | EBP | Q15125 | 3/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360466 | 0.80 | SIGMAR1 (0.72) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| SCHEMBL2360468 | 0.80 | SIGMAR1 (0.72) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| SCHEMBL3403111 | 0.80 | SIGMAR1 (0.72) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| SCHEMBL11684907 | 0.79 | SIGMAR1 (0.70) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| SCHEMBL25357939 | 0.77 | SIGMAR1 (1.00) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| SCHEMBL25358487 | 0.77 | SIGMAR1 (1.00) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| SCHEMBL25358883 | 0.77 | SIGMAR1 (0.74) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| SCHEMBL11736902 | 0.74 | SIGMAR1 (0.63) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL11733052 | 0.73 | SIGMAR1 (0.62) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 | |
| SCHEMBL25358545 | 0.72 | SIGMAR1 (0.70) | SLC18A3EBPLSIGMAR1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | claimed |
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2024-07-16 | — | — | US | disclosed |
| US-20240216553-A1 | DEVELOPMENT OF CD163 TARGETING AGENT FOR IMAGING AND THERAPY | WASHINGTON UNIVERSITY | 2024-07-04 | — | — | US | disclosed |
| US-20230112948-A1 | USE OF PRIDOPIDINE FOR TREATING ANXIETY AND DEPRESSION | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-04-13 | — | — | US | disclosed |
| US-11471449-B2 | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | SLC6A3, QDPR, PARK7 | SLC18A3 41/4885EBPL 4415/4885SIGMAR1 1492/4885 |
| US-20230112948-A1 | USE OF PRIDOPIDINE FOR TREATING ANXIETY AND DEPRESSION | DRD2, DRD4, HTR5A | SLC18A3 143/4885EBPL 3833/4885SIGMAR1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.